BRCA1: mechanisms of inactivation and implications for management of patients (Q34970470)

5 August 2017

1 reference

title

BRCA1: mechanisms of inactivation and implications for management of patients (English)

1 reference

5 August 2017

0 references

Richard D Kennedy

1

1 reference

5 August 2017

Jennifer E Quinn

series ordinal

2

1 reference

5 August 2017

Patrick G Johnston

series ordinal

3

1 reference

5 August 2017

D Paul Harkin

series ordinal

4

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

5 August 2017

1 reference

5 August 2017

360

1 reference

5 August 2017

9338

1 reference

5 August 2017

1007-1014

1 reference

Linkage of early-onset familial breast cancer to chromosome 17q21

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Evidence for a transcriptional activation function of BRCA1 C-terminal region

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

BRCA1 protein products ... Functional motifs...

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

New complexities for BRCA1 and BRCA2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

BRCA1 mutations in primary breast and ovarian carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Modifiers of risk of hereditary breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Mutations and alternative splicing of theBRCA1 gene in UK breast/ovarian cancer families

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

BRCA1 testing--advances and retreats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Genetic counselling for hereditary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

The Royal Marsden Hospital (RMH) trial: key points and remaining questions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Breast cancer screening for high-risk women: too little, too late?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Long-term follow-up of the Stockholm screening study on ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Transcriptional activation by BRCA1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Gene-Expression Profiles in Hereditary Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

BRCA-associated breast cancer in young women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Survival and tumor characteristics of German hereditary breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Frequency of BRCA1 dysfunction in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Effect of Radiotherapy After Breast-Conserving Treatment in Women With Breast Cancer and Germline BRCA1/2 Mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Brca1 controls homology-directed DNA repair

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

BRCA1 is associated with the centrosome during mitosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911087-7

7 January 2021

10.1016/S0140-6736(02)11087-7

Identifiers

DOI

1 reference

5 August 2017

1 reference